Quantum BioPharma Ltd. Other Comprehensive Income Net Of Tax Exchange Differences On Translation
Quantum BioPharma Ltd. (QNTM) reported Other Comprehensive Income Net Of Tax Exchange Differences On Translation of $40.74 thousand for the 12-month period ending 2025-12-31, per its 20-F filed 2026-03-26.
Financial Statements › Income Statement › Unrealized Gains
ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation · last filed 2026-03-26
CAD
| Period end | Other Comprehensive Income Net Of Tax Exchange Differences On Translation 12 month |
|---|---|
| 2019-12-31 | -112.69K CAD 40-F/A · filed 2020-03-17 |
USD
| Period end | Other Comprehensive Income Net Of Tax Exchange Differences On Translation 3 month | Other Comprehensive Income Net Of Tax Exchange Differences On Translation 6 month | Other Comprehensive Income Net Of Tax Exchange Differences On Translation 9 month | Other Comprehensive Income Net Of Tax Exchange Differences On Translation 12 month |
|---|---|---|---|---|
| 2025-12-31 | -$184.61K derived: 20-F 12 month − 6-K 9 month · filed 2026-03-26 | -$39.31K derived: sum of 2 quarters · filed 2026-03-26 | $44.23K derived: sum of 3 quarters · filed 2026-03-26 | $40.74K 20-F · filed 2026-03-26 |
| 2025-09-30 | $145.30K 6-K · filed 2025-11-06 | $228.84K derived: sum of 2 quarters · filed 2025-11-06 | $225.35K 6-K · filed 2025-11-06 | -$556.91K derived: sum of 4 quarters · filed 2026-03-26 |
| 2025-06-30 | $83.54K 6-K · filed 2025-08-07 | $80.05K 6-K · filed 2025-08-07 | -$702.21K derived: sum of 3 quarters · filed 2026-03-26 | $47.35K derived: sum of 4 quarters · filed 2026-03-26 |
| 2025-03-31 | -$3.49K 6-K/A · filed 2025-06-16 | -$785.76K derived: sum of 2 quarters · filed 2026-03-26 | -$36.19K derived: sum of 3 quarters · filed 2026-03-26 | -$137.28K derived: sum of 4 quarters · filed 2026-03-26 |
| 2024-12-31 | -$782.27K derived: 20-F 12 month − 6-K 9 month · filed 2026-03-26 | -$32.70K derived: sum of 2 quarters · filed 2026-03-26 | -$133.79K derived: sum of 3 quarters · filed 2026-03-26 | -$366.55K 20-F · filed 2026-03-26 |
| 2024-09-30 | $749.56K 6-K · filed 2025-11-06 | $648.48K derived: sum of 2 quarters · filed 2025-11-06 | $415.72K 6-K · filed 2025-11-06 | |
| 2024-06-30 | -$101.09K 6-K · filed 2025-08-07 | -$333.84K 6-K · filed 2025-08-07 | ||
| 2024-03-31 | -$232.75K 6-K/A · filed 2025-06-16 | |||
| 2023-12-31 | -$235.26K 20-F · filed 2026-03-26 | |||
| 2022-12-31 | $412.99K 20-F · filed 2023-03-31 | |||
| 2021-12-31 | $31.82K 20-F · filed 2023-03-31 | |||
| 2020-12-31 | $292.57K 20-F · filed 2023-03-31 | |||
| 2019-12-31 | -$84.78K 40-F · filed 2021-03-17 |